Plarium Launches Collection RPG ‘RAID: Shadow Legends’ on iOS and Android Devices
Plarium, a developer of mobile, social, and web-based games with more than 250 million users worldwide, is proud to announce the launch of RAID: Shadow Legends. Available now on the App Store and Google Play, the turn-based collection RPG invites players to fight and conquer a dark fantasy world with over 300 collectible champions across 16 factions. The game features entirely unique individual character models, deep tactics, unparalleled skill customization, and clan-driven cooperative play.
RAID is set in the realm of Teleria, tainted by a shadow cast by the Dark Lord Siroth. Players assume the role of an ancient Telerian warrior resurrected by an immortal guardian to defeat Siroth and restore peace to the realm. Along their journey, players will accumulate Shards, vessels containing the souls of past warriors, to assemble an army and battle across castles, deserts, dungeons and ancient temples guarded by foes and potential allies. Progression allows players to unravel the many layers behind the threat assailing Teleria.
RAID features an extensive story-driven single player (PvE) campaign with 12 campaign levels, each including seven stages and three difficulty levels. The narrative is written by Writers’ Guild of America-nominated Paul C.R. Monk from Assassin’s Creed: Syndicate, and features a fully-voiced cast that includes veterans from Mass Effect and The Witcher 3. The campaign is interconnected with the multiplayer (PvP) component to determine the ranking system, offering one of the most unified game experiences in the collection RPG genre. Each of the 300+ collectible characters features unique motion-capture animations produced exclusively in Plarium’s in-house studio to create distinctive character traits and personas.
“RAID is the ultimate combination of fantasy RPG and battle collection on mobile, giving players an unprecedented depth of play, endless customization of a highly diverse cast of Champions, and thousands of hours of gameplay. They’ll battle tons of challenging bosses and other players on their quest, in a world with seemingly endless content,” says Nick Day, Creative Director at Plarium. “With player choice at the core of RAID’s experience, we took every liberty to establish a unique setting in which to explore, experiment, and win.”
Key gameplay features of RAID: Shadow Legends include:
- Over 300 collectible characters: Collect hundreds of good, evil, or neutral warriors from 16 factions. Assemble the best teams of Barbarians, Skinwalkers, Undead, Knights, Elves, and more to defeat enemies and recruit them to your army.
- 1+ Million Champion Builds: Enjoy unparalleled RPG skill customization and explore thousands of combinations of skills, artifacts, and mastery paths to give each Champion millions of possible builds.
- Massive PvE Campaign Map: Experience epic dark fantasy through 12 spectacular locations spread over a sprawling, fully-voiced story campaign. Special time-specific dungeons reward players with rare items and artifacts to power their Champions.
- PVP Arena & Rankings: Go head-to-head with other players to unlock special gear and climb the rankings in intense arena battles. The higher the ranking, the increased chance of rare gear and item drops.
- Deep Strategic Gameplay: Succeed by combining skill and knowledge. Train the right teams of Champions for the right challenges, and teach them devastating special skills, AOE attacks, and healing powers. Then unleash them in arena battles, dungeon runs, clan boss fights, and story missions.
- A Complete Clan Experience: RAID alongside your friends as you climb the Clan Rankings, earn Clan Activity bonuses, and cooperate on dungeon runs against epic bosses.
RAID: Shadow Legends is now available for users around the globe in Chinese (Simplified & Traditional), English, French, German, Italian, Japanese, Korean, Portuguese (Brazilian), Russian, Spanish, Ukrainian and Turkish.
About Plarium
Founded in 2009, Plarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore and casual gamers worldwide. With over 250 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. Plarium employs more than 1200 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our mobile and social games are available on all major social networks, including Facebook, VKontakte, Odnoklassniki and Mail.ru, as well as web browsers, iOS and Android. Plarium was acquired by Aristocrat in October 2017 and operates as a wholly owned subsidiary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190228005070/en/
Contact information
Media Contacts:
Deanna Dweck
Plarium
Phone: +972 9
9540211 ext. 116
Email: deanna@plarium.com
Ross
Blume
Fusion PR for Plarium
Phone: +1-310-481-1431 ext. 18
Email:
ross.blume@fusionpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 115.5.2025 00:03:00 EEST | Press release
Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo through eight weeks of treatment. NT1 is a severe, chronic neurological condition caused by a significant loss of orexin-producing neurons, resulting in low levels of orexin leading to EDS, cataplexy (sudden loss of muscle tone), cognitive symptoms, disrupted nighttime sleep, hallucinations that occur as one falls asleep or wakes up and sleep paralysis.T
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 23:05:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation science and patient-focused innovation. “With three cornerstone hematology assets – BRUKINSA, sonrotoclax and BGB-16673 – we are advancing a potentially best-in-class portfolio in B-cell malignancies,” said Lai Wang, Ph.D. Global Head of R&D. “At EHA 2025, we’ll share 31 accepted ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom